Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology · Chronic Myelomonocytic Leukemia

Why Do I Need a Bone Marrow Biopsy for CMML Diagnosis?

At a Glance

A bone marrow biopsy is an important part of diagnosing CMML, but it is not used alone. Doctors combine liquid and solid marrow findings with blood counts, symptoms, medical history, and genetic tests to confirm CMML and guide risk assessment and treatment planning.

A bone marrow biopsy is an essential part of the diagnostic process for chronic myelomonocytic leukemia (CMML). However, the biopsy does not diagnose CMML on its own. Instead, your care team interprets the bone marrow results together with your blood tests (such as persistent high levels of monocytes), your symptoms, and your medical history [1] [2]. This combined information helps confirm the diagnosis, rule out other conditions, and determine your specific disease subtype or risk level [3].

What the Biopsy Shows

During the procedure, your doctor will collect two types of samples, usually from the back of your hip bone. These are evaluated under a microscope and sent for advanced laboratory testing.

  • The Aspirate (Liquid Marrow): The doctor uses a syringe to pull out a small amount of liquid bone marrow. This sample is crucial for counting blasts and promonocytes (immature blood cells) [4]. For a CMML diagnosis, the blast count must be below 20% in both the blood and the bone marrow [2]. The aspirate also helps the pathologist look for dysplasia—cells that look abnormal in shape or size [2].
  • The Core Biopsy (Solid Marrow): A hollow needle removes a small, solid piece of bone and marrow. This shows the overall structure of the marrow and whether there is hyperplasia (overcrowding of cells). It also reveals whether there is fibrosis (scarring in the marrow) [4] [5]. If your marrow has severe fibrosis, it can sometimes be difficult to draw out liquid (a “dry tap”), making this solid core sample especially important for your diagnosis.
  • Genetic and Molecular Testing: The samples are also used to look for acquired (not inherited) DNA mutations and chromosome changes [1] [6]. Doctors look for evidence of clonality, which means a population of abnormal cells that all descended from a single mutated cell. Not every patient with CMML has a detectable mutation, so a negative genetic test does not mean you do not have the disease. However, finding these changes can help with risk assessment and treatment planning.

Preparing for the Procedure

It is important to provide your care team with a complete list of your prescription drugs, over-the-counter medicines, and supplements. If you take blood thinners, aspirin, or anti-inflammatory drugs, do not stop them on your own. Because CMML can sometimes cause low platelet counts, your bleeding risk is highly individualized, and your doctor will give you a specific plan for which medications to pause [7] [8].

If you are feeling anxious about the procedure or worried about pain, ask your clinic about pain management options in advance. While many biopsies are done with local anesthetic alone, some clinics offer sedation or anti-anxiety medications [9]. Keep in mind that sedation is not available everywhere, and if you receive it, you will likely need to fast beforehand and have someone drive you home.

What to Expect During the Biopsy

The procedure itself typically takes about 5 to 30 minutes, though your total appointment will be longer [10].

The doctor will inject a local anesthetic (like lidocaine) to numb your skin and the surface of the bone. While this helps reduce surface pain, pulling the liquid marrow often causes a brief, sharp pain or a deep pulling sensation that the numbing medicine cannot completely block [9].

Recovery and Aftercare

After the biopsy, a tight compression dressing is usually applied to the site. Depending on your clinic’s protocols and whether you received sedation, you may be asked to lie on your back or rest in the clinic for a short period of observation to apply pressure and prevent bleeding [11].

Bleeding complications are very uncommon in routine procedures, but your team will give you instructions for home care [7]. It is normal to feel some soreness or bruising at the biopsy site for a few days [12].

When to seek immediate medical attention:

  • Bleeding that does not stop after applying firm pressure [13]
  • Fever
  • Expanding swelling, spreading redness, warmth, or drainage at the biopsy site
  • Severe or rapidly worsening pain

When Will I Get My Results?

Because the bone marrow samples go through different types of testing, turnaround times vary by laboratory, and results often arrive in stages [14]:

  • Morphology (Cell Appearance): Preliminary cell counts from the liquid aspirate are often available first, sometimes within a few days [15] [16].
  • Core Biopsy Details: The solid bone sample takes slightly longer to process because the bone must be decalcified before it can be evaluated [14].
  • Cytogenetics and Sequencing: Advanced tests, like karyotyping (looking at whole chromosomes) and Next-Generation Sequencing (NGS, which looks for specific DNA mutations), take the longest [17]. It can take a few weeks for these genetic reports to be completed [18].

Your final diagnosis and treatment plan will be based on the integrated report that combines your blood work, morphology, and genetic findings. Your doctor will explain which results are preliminary and which are still pending.

Common questions in this guide

Why is a bone marrow biopsy needed to diagnose CMML?
The biopsy shows how blood cells are developing, how many immature cells are present, and how the marrow is structured. Doctors combine these findings with blood counts, symptoms, medical history, and genetic testing because the biopsy does not diagnose CMML by itself.
What is the difference between a bone marrow aspirate and a core biopsy?
An aspirate is a small amount of liquid marrow used to count immature cells and look for abnormal cell development. A core biopsy is a solid piece of bone and marrow that shows the marrow’s structure, overcrowding, and scarring; it can be especially important if no liquid can be drawn.
Can a negative genetic test rule out CMML?
No. Doctors use the samples to look for DNA mutations and chromosome changes that can support diagnosis and help estimate risk and plan treatment, but some people with CMML do not have a detectable mutation. These acquired changes develop in the abnormal cells rather than being inherited.
How should I prepare for a CMML bone marrow biopsy?
Tell your care team about every prescription medicine, over-the-counter product, vitamin, and supplement you take. Do not stop blood thinners, aspirin, or anti-inflammatory medicines on your own; your doctor will give you instructions and explain fasting and a driver if sedation is offered.
What does a CMML bone marrow biopsy feel like, and how long does it take?
Local anesthetic numbs the skin and surface of the bone, but removing liquid marrow can cause brief sharp pain or a deep pulling sensation. The biopsy itself usually takes about 5 to 30 minutes, although the full appointment may take longer.
When should I seek medical help after a bone marrow biopsy?
Contact your care team or seek urgent medical attention for bleeding that does not stop with firm pressure, fever, increasing swelling, spreading redness or warmth, drainage, or severe or rapidly worsening pain. Mild soreness or bruising at the site for a few days is common.
How long will CMML bone marrow biopsy results take?
Preliminary cell findings may be available within a few days, while the core biopsy and chromosome or DNA tests usually take longer. Some advanced genetic results can take a few weeks, and your final diagnosis and treatment plan are based on the integrated results.

Get notified when new evidence is published on chronic monocytic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.

    Tremblay D, Rippel N, Feld J, et al.

    The oncologist 2021; (26(5)):406-421 doi:10.1002/onco.13769.

    PMID: 33792103
  2. 2

    Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.

    Patnaik MM, Tefferi A

    American journal of hematology 2024; (99(6)):1142-1165 doi:10.1002/ajh.27271.

    PMID: 38450850
  3. 3

    Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.

    Shallis RM, Siddon AJ, Zeidan AM

    Current hematologic malignancy reports 2021; (16(3)):276-285 doi:10.1007/s11899-021-00632-6.

    PMID: 33890194
  4. 4

    CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.

    Guastafierro V, Ubezio M, Manes N, et al.

    Leukemia & lymphoma 2023; (64(9)):1566-1573 doi:10.1080/10428194.2023.2227750.

    PMID: 37395413
  5. 5

    Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.

    Petrova-Drus K, Chiu A, Margolskee E, et al.

    Oncotarget 2017; (8(61)):103274-103282 doi:10.18632/oncotarget.21870.

    PMID: 29262560
  6. 6

    [MDS & CMML: Diagnostic and classification].

    Wagner-Ballon O, Kosmider O

    Bulletin du cancer 2023; (110(11)):1106-1115 doi:10.1016/j.bulcan.2023.02.030.

    PMID: 37453834
  7. 7

    Bone Marrow Aspiration and Biopsy Performed by RNs: A Review of Clinical Practice.

    Draganski E, Deason T, Craig FE

    The American journal of nursing 2019; (119(9)):47-53 doi:10.1097/01.NAJ.0000580260.18537.ca.

    PMID: 31449123
  8. 8

    Complications associated with improper palpation-guided iliac bone marrow biopsy tracts identified on follow-up imaging.

    Khdhir M, Jabbour Y, Azzi C, et al.

    Skeletal radiology 2022; (51(11)):2155-2166 doi:10.1007/s00256-022-04078-6.

    PMID: 35612650
  9. 9

    Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial.

    Cerchione C, Martinelli G, Picardi M, et al.

    Journal of clinical medicine 2020; (9(2)) doi:10.3390/jcm9020395.

    PMID: 32024148
  10. 10

    Enhancing conventional biopsies: ultrasound-guided percutaneous bone marrow biopsy and aspiration.

    Cushman C, Smith A, Morris K, et al.

    Journal of ultrasound 2026; (29(2)):309-315 doi:10.1007/s40477-026-01125-z.

    PMID: 41845083
  11. 11

    Comparison of Bleeding, Hematoma, Pain, and Discomfort After Bone Marrow Examination With or Without Sandbag Compression.

    Lee SH, Kim CG, Kwon J, et al.

    Asian nursing research 2021; (15(2)):150-156 doi:10.1016/j.anr.2021.02.004.

    PMID: 33609762
  12. 12

    Pain Persisting After Bone Marrow Aspiration and Biopsy: Clinical Features, Pain Phenotypes, and Prospective Outcomes.

    Ersoy Dursun F, Doğruöz Karatekin B

    Journal of pain research 2026; (19()):604699 doi:10.2147/JPR.S604699.

    PMID: 42694960
  13. 13

    Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome.

    Kogan L, Price R, Kotchetkov R

    Frontiers in oncology 2024; (14()):1326209 doi:10.3389/fonc.2024.1326209.

    PMID: 38361779
  14. 14

    An Extensive Analysis and Comparison of Bone Marrow Aspiration and Bone Marrow Trephine Biopsy at a Tertiary Care Hospital in Jharkhand for Various Hematological and Non-hematological Illnesses.

    Jawed MA, Paswan MK, Mahto SK, et al.

    Cureus 2024; (16(6)):e62661 doi:10.7759/cureus.62661.

    PMID: 39036242
  15. 15

    Diagnostic importance of bone marrow aspiration evaluation: A single-center study.

    Dogan A, Demircioglu S

    Pakistan journal of medical sciences 2022; (38(4Part-II)):811-815 doi:10.12669/pjms.38.4.4797.

    PMID: 35634633
  16. 16

    ICH-ISHBT Recommendations On Bone Marrow Aspiration/Imprint Smear Synoptic Reporting.

    Pati HP, Padhi S, Sharma P, et al.

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2026; (42(5)):1606-1615 doi:10.1007/s12288-026-02551-z.

    PMID: 42712573
  17. 17

    A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms.

    Liquori A, Lesende I, Palomo L, et al.

    Cancers 2021; (13(8)) doi:10.3390/cancers13081947.

    PMID: 33919541
  18. 18

    Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

    Palomo L, Ibáñez M, Abáigar M, et al.

    British journal of haematology 2020; (188(5)):605-622 doi:10.1111/bjh.16175.

    PMID: 31621063

This page is for informational purposes only and does not constitute medical advice. Your hematology team can explain your CMML biopsy plan, medication instructions, and when to seek care.